Browse drugs

…ion-level assessment.86 Similarly, 177Lu-DOTATATE combined with nivolumab has shown tolerability and preliminary activity in pulmonary ne…

… during treatment with PD-1 inhibitors. Eight patients received pembrolizumab (six as monotherapy and two in combination with carboplatin plu…

…esectable CSCC. Neoadjuvant ICIs studies, including cemiplimab, pembrolizumab, and nivolumab±ipilimumab, have reported consistent and strikin…

…ombinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16 µg/kg: Cohort A1 and B1 and 24…

…low adrenocorticotropic hormone (ACTH) level and no response to cosyntropin, confirming central adrenal insufficiency. Other pituitary horm…

…iltration.Most strikingly, in a subset of patients treated with pembrolizumab, high CXCR4 expression was associated with improved survival ou…

…with reduced survival in patients with lung cancer treated with pembrolizumab plus platinum-based chemotherapy. In preclinical models, both g…

…by IHC stain intensity. Information for real-world survival and pembrolizumab treatment was obtained from the CODEai database using insurance…

…nge of herding lies in duration and scale. Since the success of pembrolizumab, with at least 14 PD-1/PD-L1 inhibitors now approved, herding h…

…cells. We report the case of a man in his 60s receiving the ICI pembrolizumab for lung adenocarcinoma, who presented with acute renal failure…

…gimens for rNSCLC were durvalumab, nivolumab, pembrolizumab and toripalimab. The estimated hazard ratio of immunotherapy regimens for the a…

…ucted, including all patients who received at least one dose of pembrolizumab, nivolumab, or atezolizumab as first-line treatment for metasta…